Effect of a water-maze procedure on the redox mechanisms in brain parts of aged rats

Age-related biochemical dysfunction in 6-OHDA model rats subject to induced- endurance exercise

Exercise can alleviate the disorders considered as the normal consequences of aging. Whether or not the treadmill endurance training affects the biochemical markers in the Parkinson's disease model rats after the 6-hydroxydopamine (6-OHDA) injection is assessed in this article. The experimental groups of N=8 rats consist of 1) Saline and Young sedentary (S-Young); 2) Saline and Old sedentary (S-Old); 3) Young and 6-OHDA without exercise (Y); 4) Young and 6-OHDA with exercise (YE); 5) Old and 6-OHDA without exercise (O); and 6) Old and 6-OHDA with exercise (OE). An 8 μg of 6-OHDA is injected into the right MFB. The rotation due to apomorphine, weight variation, and some biochemical expression are measured in the rats' striatum. Exposure to 6-OHDA: increase weight loss by (%8) and rotation by (%90), reduce the protein levels of Bdnf by (30%), Th by (43%), and Tfam by (24%), in aging rats (P<0.05). The P53 level rose after the injection compared with the same Saline group (Old rats: 27% and Young rats: 14%), the highest in the O group. The findings indicate that endurance exercise amends the mitochondrial parameters and the apomorphine-induced rotation impairments in the presence of 6-OHDA injection. These positive effects of treadmill running in unilateral 6-OHDA lesioned rat model are age-dependent and are more significant in younger rats.

Targeting GSNOR for functional recovery in a middle-aged mouse model of stroke

The nitric oxide (NO) metabolome and the NO metabolite-based neurovascular protective pathways are dysregulated after stroke. The major NO metabolite S-nitrosoglutahione (GSNO) is essential for S-nitrosylation-based signaling events and the inhibition of S-nitrosoglutahione (GSNO)-metabolizing enzyme GSNO reductase (GSNOR) provides protective effects following cardiac ischemia. However, the role of GSNOR and GSNOR inhibition-mediated increased GSNO/S-nitrosylation is not understood in neurovascular diseases such as stroke. Because age is the major risk factor of stroke and recovery in aged stroke patients is low and slow, we investigated the efficacy of GSNOR inhibition using a GSNOR selective inhibitor N6022 in a clinically relevant middle-aged cerebral ischemia and reperfusion (IR) mouse model of stroke. N6022 (5 mg/kg; iv) treatment of IR mice at 2 h after reperfusion followed by the treatment of the same dose daily for 3 days reduced the infarct volume and decreased the neurological score. Daily treatment of IR animals with N6022 for 2 weeks significantly improved neurological score, brain infarctions/atrophy, survival rate, motor (measured by cylinder test) and cognitive (evaluated by novel object recognition test) functions which paralleled the decreased activity of GSNOR, reduced levels of peroxynitrite and decreased neurological score. These results are the first evidence of a new pathway for the treatment of stroke via the inhibition of GSNOR. Based on the efficacy of N6022 in the stroke animal model and its use in human therapeutic studies without toxicity, we submit that GSNOR is a druggable target, and N6022 is a promising drug candidate for human stroke therapy.

Developmental suppression of forebrain trkA receptors and attentional capacities in aging rats: A longitudinal study

Basal forebrain (BF) cholinergic neurons innervating the cortex regulate cognitive, specifically attentional, processes. Cholinergic atrophy and cognitive decline occur at an accelerated pace in age-related neurodegenerative disorders such as Alzheimer's disease; however, the mechanism responsible for this phenomenon remains unknown. Here we hypothesized that developmental suppression of nerve growth factor signaling, mediated via tropomyosin-related kinase A (trkA) receptors, would escalate age-related attentional vulnerability. An adeno-associated viral vector expressing trkA shRNA (AAV-trkA) was utilized to knockdown trkA receptors in postnatal rats at an ontogenetic time point when cortical cholinergic inputs mature, and the impact of this manipulation on performance was assessed in animals maintained on an operant attention task throughout adulthood and until old (24 months) age. A within-subject comparison across different time points illustrated a gradual age-related decline in attentional capacities. However, the performance under baseline and distracted conditions did not differ between the AAV-trkA-infused and animals infused with a vector expressing shRNA against the control protein luciferase at any time point. Additional analysis of cholinergic measures conducted at 24 months showed that the capacity of cholinergic terminals to release acetylcholine following a depolarizing stimulus, cortical cholinergic fiber density and BF cholinergic cell size remained comparable between the two groups. Contrary to our predictions, these data indicate that developmental BF trkA disruption does not impact age-related changes in attentional functions. It is possible that life-long engagement in cognitive activity might have potentially rescued the developmental insults on the cholinergic system, thus preserving attentional capacities in advanced age.